A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (PALLET)

Clinical Trial ID NCT02296801

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.	Breast Cancer Res	2016	0.87
2	Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.	Clin Cancer Res	2015	0.79
3	Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer.	Onco Targets Ther	2016	0.75
4	First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.	P T	2015	0.75